You are here

Article info

Article menu

Download PDFPDF

Infectious diseases
Viewpoint
For patients with rheumatic disease and hepatitis C infection: the end of interferon

Authors

  • Leonard H Calabrese Cleveland Clinic Lerner, College of Medicine of Case Western Reserve University, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Patrice P Cacoub Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, Paris, France INSERM, UMR_S 959, Paris, France CNRS, FRE3632, Paris, France Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Leonard H Calabrese; calabrl{at}ccf.org
View Full Text

Citation

Calabrese LH, Cacoub PP
For patients with rheumatic disease and hepatitis C infection: the end of interferon
RMD Open 2015;1:e000008. doi: 10.1136/rmdopen-2014-000008

Publication history

  • Received October 21, 2014
  • Accepted December 7, 2014
  • First published February 18, 2015.
Online issue publication 
February 21, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/